Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643299 · ClinicalTrials.gov registry record · Phase 2
Probiotic Use for Recovery Enhancement From Long COVID-19
A Phase 2 study of Post-Acute COVID-19 Syndrome, sponsored by Rush University Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT06643299: Active Phase 2 study of Post-Acute COVID-19 Syndrome, sponsored by Rush University Medical Center.
NCT06643299 is a Phase 2 study of Post-Acute COVID-19 Syndrome that is active but no longer recruiting, run by Rush University Medical Center. The registered enrollment target is 180 participants, below the 831-participant average among 14 other Post-Acute COVID-19 Syndrome trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06643299, a Phase 2 study of Post-Acute COVID-19 Syndrome, is active but no longer recruiting, sponsored by Rush University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.
Primary Outcome
Defined as the percentage change from moderate-to-severe Long COVID to mild Long COVID using the Long COVID Symptoms and Severity Score (LC-SSS) tool between groups with subgroup analysis by Long COVID trajectory
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Probiotic Agent
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT06643299 still lists
NCT06643299 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 831-participant average among 14 other Post-Acute COVID-19 Syndrome trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Post-Acute COVID-19 Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06643299 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06643299 about?
NCT06643299 is a clinical study titled "Probiotic Use for Recovery Enhancement From Long COVID-19". The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.
What is the current status of trial NCT06643299?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-05-13. Estimated completion is 2026-07.
What conditions does trial NCT06643299 study?
This clinical trial studies the following conditions: Post-Acute COVID-19 Syndrome.
What interventions are being tested in trial NCT06643299?
The interventions under investigation include: Placebo (OTHER), Probiotic Agent (DRUG).
Who is sponsoring clinical trial NCT06643299?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06643299 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-Acute COVID-19 Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06643299's enrollment target sits among peer trials
180 5th of 14 higher than 10 of 14 other Post-Acute COVID-19 Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post-Acute COVID-19 Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction
ACTIVE NOT RECRUITING · Phase 2
-
Brain-Training Treatment for Long COVID in Older Adults
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Long COVID Brain Fog: Cognitive Rehabilitation Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI